Target enzyme mutations are the molecular basis for resistance towards pharmacological inhibition of nicotinamide phosphoribosyltransferase

Target enzyme mutations are the molecular basis for resistance towards pharmacological inhibition of nicotinamide phosphoribosyltransferase

<p>Abstract</p> <p>Background</p> <p>Inhibitors of nicotinamide phosphoribosyltransferase (NAMPT) are promising cancer drugs currently in clinical trials in oncology, including APO866, CHS-828 and the CHS-828 prodrug EB1627/GMX1777, but cancer cell resistance to these d...

Full description

Bibliographic Details
Main Authors: Christensen Mette K, Imai Shin-Ichiro, Yoshino Jun, Kiess Wieland, Garten Antje, Petersen Jakob G, Olesen Uffe H, Fristrup Peter, Thougaard Annemette V, Björkling Fredrik, Jensen Peter B, Nielsen Søren J, Sehested Maxwell
Format: Article
Language:English
Published: BMC 2010-12-01
Series:BMC Cancer
Online Access:http://www.biomedcentral.com/1471-2407/10/677

Internet

http://www.biomedcentral.com/1471-2407/10/677

Similar Items